The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
The twin brother of the police officer shot and blinded by gunman Raoul Moat says his family are still waiting for justice five years later.
The success of the No camp is mainly due to Tsipras convincing people a No vote will strengthen their hands in negotiations.
As we move into the weekend, expect things to get rather more unsettled weather-wise - thought it will stay hot and humid for some.